MPO and type 2 diabetes mellitus: Mechanistically, it has been shown that treatment with GLP-1 RA reduced ROS production and recovered mitochondrial membrane potential, mitochondrial respiration, and myeloperoxidase (MPO) levels in persons with type 2 diabetes [48], in line with our earlier findings regarding mitochondrial metabolomics [32].